Information about Igs Pharma
My details
*
*
*

Company information

Status
Active

Enterprise number

BE0739.742.487

VAT liability
Yes
Established
18-12-2019
Last balance sheet year
2025
Company size
Small 1 FTE
Legal form
Société à responsabilité limitée (SRL)
Commercial name
Ikram Laâroussi
Principal activity
Retail sale of pharmaceutical products
Health barometer
Credit limit
Detailpage

Are you looking for more information about this company?

  • Consult health at a glance

  • Choose quick insights or granular details

  • Get updates on important developments

7-day free trial, no credit card required.

Financial data from Igs Pharma

2025 2024 2023 2022
Income statement
Profit/Loss € -97,048 30% € -138,038 < -1000% € 10,484 -16% € 12,480
Gross margin € 86,248 69% € 51,076 -75% € 202,939 36% € 149,339
Balance sheet
Balance sheet total € 656,335 -31% € 949,580 -4% € 991,527 -3% € 1,027,325
Equity € -155,693 -165% € -58,645 -174% € 79,393 15% € 68,909
Debts € 812,028 -19% € 1,008,225 11% € 912,134 -5% € 958,415
Other
Employees 1 1 1.3 1

Publications from Igs Pharma

Date Publication
20-12-2019 Rubric Constitution (New Juridical Person, Opening Branch, etc...) (FR)

Frequently asked questions

What is the VAT number of Igs Pharma?
The VAT number of Igs Pharma is BE 0739.742.487.
Wat is the PEPPOL ID of Igs Pharma?
The PEPPOL ID of Igs Pharma is 0208:0739742487. Log in or start a free trial to see the full overview.
When was Igs Pharma founded?
Igs Pharma was founded on 18-12-2019.
What is the address of Igs Pharma?
The current registered office of Igs Pharma is located at Rue de Bosnie 104, 1060 Saint-Gilles.
When was the last time Igs Pharma filed their annual financial statements?
The most recent financial statements of Igs Pharma were filed on 08-09-2026.
How many employees does Igs Pharma have?
There are 1 FTEs working at Igs Pharma according to the staff figures in the most recent financial statements.
What is the annual turnover of Igs Pharma?
At the time of its most recent financial statements, Igs Pharma did not publish any turnover figures. Igs Pharma reported a gross margin of €86,247.71.